Barclays PLC Shattuck Labs, Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, Barclays PLC holds 54,311 shares of STTK stock, worth $62,457. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54,311
Previous 54,311
-0.0%
Holding current value
$62,457
Previous $189,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding STTK
# of Institutions
80Shares Held
28.8MCall Options Held
300Put Options Held
1.2K-
Prosight Management, LP Dallas, TX5.68MShares$6.53 Million5.32% of portfolio
-
Redmile Group, LLC San Francisco, CA5.62MShares$6.46 Million1.28% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.9MShares$3.33 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.47MShares$2.85 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.4MShares$2.76 Million0.0% of portfolio
About Shattuck Labs, Inc.
- Ticker STTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,382,000
- Market Cap $48.7M
- Description
- Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...